Ophthotech Partners with UMass to Develop ‘Minigene’ Therapy for Retinal Disease

March 2, 2018: By Jon Swedien

Ophthotech and the University of Massachusetts have agreed to a gene therapy research collaboration that will focus on the school’s “minigene” therapy and will target retinal disease, the company announced Feb. 27.

The minigene approach is designed to deliver a shortened but functional form of a large gene packaged in a standard-size adeno-associated virus (AAV) delivery vector commonly used in gene therapy, Ophthotech said. The strategy may offer a solution for diseases difficult to treat through conventional AAV gene replacement therapy, the company said.

The partnership includes a series of sponsored research agreements with the university’s medical school and its Horae Gene Therapy Center. The research agreements will use the minigene therapy and other novel gene-delivery technologies, Ophthotech said.

As a condition of each research agreement, the university has granted Ophthotech an option to obtain an exclusive license to any patents or patent applications that result from the collaboration.

Ophthotech said professor Guangping Gao, PhD, and associate professor Hemant Khanna, PhD, will lead the collaboration. The company said Gao is a pioneer in the development of a novel AAV family for gene therapy and that Khanna’s research focuses on the molecular mechanism of inherited ocular disorders.

The deal could signify a new direction for Ophthotech, which until August 2017 had been developing Fovista. The proposed combination treatment for wet age-related macular degeneration failed in two Phase III trials in combination with Lucentis. It was among several heralded proposed combination treatments for retinal disease that failed in Phase III in 2017.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Inks Deal with Express Scripts Expanding Vyzulta Coverage

Melgen Seeks Bond, Appeals Conviction on Charges of Medicare Fraud

Avedro, FDA Agree on Design, Size of First Pivotal Phase III Trial for Epi-on Cross-linking

Iridex Reports 2017 Revenues of $41.6 Million

Bar-Ilan University Announces Nano-Drop Candidate to Correct Refractive Error

Essex Bio-Technology Agrees to Invest $5 Million in MeiraGTx, Developer of Gene Therapies

Clearside Biomedical Announces $85 Million Public Offering

ViewPoint Raises $35 Million for Topical Treatment Candidate for Cataracts, Presbyopia

Okogen Raises $10 Million in Series A Round for Viral Conjunctivitis Candidate

SightLife Surgical Acquires KAMRA Corneal Inlay from AcuFocus

Major Leaguer Tommy Pham Plays Through Keratoconus

Glaukos Reports 2017 Net Sales of $159.3 Million

Imprimis Posts 2017 Revenues of $26.77 Million, a 34 Percent Increase

STAAR’s 2017 Net Sales Total $90.6 Million

US FDA Warns Consumers Not to Use Products from Cantrell Drug Company

IDx’ AI-Based Diagnostics System Meets Endpoints in Pivotal Trial for DR

Aerie Plans to Launch Rhopressa in Q2-2018, Expects 2018 Revenues of $20 Million to $30 Million

Valeant Reports 2017 Revenues of $8.72 Billion, a Decline of 10 Percent

Carl Zeiss Meditec Reports $359.7 Million in Revenues for First Quarter of FY2018, a 5.3 Percent Increase

Ophthotech Partners with UMass to Develop ‘Minigene’ Therapy for Retinal Disease

Coming soon

2018 IOL Report: A Global Market Analysis for 2017 to 2023